Ono Pharmaceutical Co., Ltd.

Satonori Higuchi

Masaki Asada

Kousuke Tani

Tohru Kotani

Hirotsugu Takano

Masaya Hirobe

Kazuhiro Fuchibe

Ryo Oikawa

Atsushi Naganawa

Yasuhiro Takeda

Keisuke Hanada

A medicinal agent for the prevention and/or treatment of diseases caused by EPreceptor activation is disclosed. A compound having antagonistic activity against the EPreceptor is contained as an active ingredient in the medicinal agent. The compound represented by the following general formula (I) as defined in the specification, a salt, an N-oxide, or a solvate thereof, or a prodrug of these is useful as a medicinal component having antagonistic activity against the EPreceptor for the prevention and/or treatment of diseases caused by EPreceptor activation.

Tricyclic spiro compound

A compound represented by general formula (I): (wherein in the formula, all the symbols have the same meanings as those described in the specification), or a pharmaceutically acceptable salt thereof is useful as a medicament's active ingredient having an EPreceptor antagonistic activity, in preventing and/or treating disease caused by activation of an EPreceptor.

EP4 antagonist

An object of the present invention is to provide a DP receptor antagonist. A compound represented by general formula (I): 

DP antagonist

A medicinal agent for the prevention and/or treatment of diseases caused by EPreceptor activation is disclosed. A compound having antagonistic activity against the EPreceptor is contained as an active ingredient in the medicinal agent. The compound represented by the following general formula (I) as defined in the specification, a salt, an N-oxide, or a solvate thereof, or a prodrug of these is useful as a medicinal component having antagonistic activity against the EPreceptor for the prevention and/or treatment of diseases caused by EPreceptor activation. 

A medicinal agent for the prevention and/or treatment of diseases caused by EPreceptor activation. A compound having antagonistic activity against the EPreceptor is contained as an active ingredient in the medicinal agent. The compound represented by the following general formula (I) as defined in the specification, a salt, an N-oxide, or a solvate thereof, or a prodrug of these is useful as a medicinal component having antagonistic activity against the EPreceptor for the prevention and/or treatment of diseases caused by EPreceptor activation. 

Growing community of inventors

Osaka, Japan

Satonori Higuchi